Squarepoint
ARTV

Squarepoint’s Artiva Biotherapeutics ARTV Stock Holding History

Squarepoint’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
+14,855
New +$135K ﹤0.01% 4137
2025
Q3 		– Sell
-41,395
Closed -$62.5K – 5125
2025
Q2 		$62.5K Buy
+41,395
New +$86.9K ﹤0.01% 4272

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Squarepoint's ARTV Position: Q2 2026 in Review

Squarepoint opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 14,855 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #4137 among its holdings. This is a return to the name: Squarepoint previously reported a position in ARTV as recently as Q2 2025.

Squarepoint first reported a position in ARTV in Q2 2025 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Squarepoint held 14,855 shares of Artiva Biotherapeutics worth $144K as of Q2 2026.
  • Artiva Biotherapeutics was a new Squarepoint position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4137 holding.
  • Squarepoint first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.